What is the primary advantage of the recombinant zoster vaccine (Shingrix) compared with the live vaccine (Zostavax)?

What is the primary advantage of the recombinant zoster vaccine (Shingrix) compared with the live vaccine (Zostavax)?

• A. Increased efficacy (97% vs 51%)
• B. Shorter duration of protection
• C. Requires fewer doses
• D. Higher cost

Answer: (A)

Shingrix offers far stronger protection because it is a recombinant, non-live vaccine using a piece of the varicella-zoster virus (glycoprotein E) with a potent adjuvant that drives a robust immune response. This design yields very high efficacy in adults 50 and older—around 97% in preventing shingles and strong protection against postherpetic neuralgia—across age groups. In contrast, Zostavax is a live attenuated vaccine with about half the protection that wanes with age. While Shingrix does require two doses (a schedule that contributes to sustained immunity) and is not a live vaccine (which affects who can safely receive it), the standout advantage is the much higher and more durable efficacy.

Shingrix offers far stronger protection because it is a recombinant, non-live vaccine using a piece of the varicella-zoster virus (glycoprotein E) with a potent adjuvant that drives a robust immune response. This design yields very high efficacy in adults 50 and older—around 97% in preventing shingles and strong protection against postherpetic neuralgia—across age groups. In contrast, Zostavax is a live attenuated vaccine with about half the protection that wanes with age. While Shingrix does require two doses (a schedule that contributes to sustained immunity) and is not a live vaccine (which affects who can safely receive it), the standout advantage is the much higher and more durable efficacy.